Removal of organic matter and nitrogen from dairy effluents in a structured bed reactor operated with intermittent aeration.

The objective of this research was to evaluate the performance of a structured bed reactor (SBRIA), carried out with intermittent aeration (IA), in the removal of organic matter and nitrogen from dairy effluent, when run with different organic loading rates (OLR). The SBRIA was operated for 227 days, with 2:1 AI cycles (2 h with aeration on and 1 h off) and Hydraulic Retention Time (HRT) of 16 h. Three phases, with different OLR, were evaluated: phases A (1000 gCOD m-3 day-1 - 63 days), B (1400 gCOD m-3 day-1 - 94 days), and C (1800 gCOD m-3 day-1 - 70 days). The percentage of COD, NH4+-N removal, and nitrogen removal, respectively, were above 85 ± 7%, 73 ± 27%, and 83 ± 5, in all phases. There was no accumulation of the oxidized forms of nitrogen in the reactor. The kinetic test, performed to evaluate the nitrification and denitrification in the system, indicated that even in dissolved oxygen concentrations of 4.5 mg L-1, it was possible to obtain the denitrification process in the system. The results demonstrate that the reactor under study has positive characteristics to be used as an alternative for removing the removal of organic material and nitrogen in the biological treatment of dairy effluents.

A new extracellular glutaminase and urease-free L-asparaginase from Meyerozyma guilliermondii.

L-Asparaginase (L-ASNase) is a potent chemotherapeutic drug employed to treat leukemia and lymphoma. Currently, L-ASNases for therapeutic use are obtained from Escherichia coli and Dickeya chrysanthemi (Erwinia chrysanthemi). Despite their therapeutic potential, enzymes from bacteria are subject to inducing immune responses, resulting in a higher number of side effects. Eukaryote producers, such as fungi, may provide therapeutic alternatives through enzymes that induce relatively less toxicity and immune responses. Additional expected benefits from yeast-derived enzymes include higher activity and stability in physiological conditions. This work describes the new potential therapeutic candidate L-ASNase from the yeast Meyerozyma guilliermondii. A statistical approach (full factorial central composite design) was used to optimize L-ASNase production, considering L-asparagine and glucose concentration, pH of the medium, and cultivation time as independent factors. In addition, the crude enzymes were biochemically characterized, in terms of temperature and optimal pH, thermostability, pH stability, and associated glutaminase or urease activities. Our results showed that enzyme production increased after supplementing a pH 4.0 medium with 1.0% L-asparagine and 0.5% glucose during 75 h of cultivation. Under these optimized conditions, L-ASNase production reached 26.01 U mL-1, which is suitable for scale-up studies. The produced L-ASNase exhibits maximal activity at 37 °C and pH 7.0 and is highly stable under physiological conditions. In addition, M. guilliermondii L-ASNase has no associated glutaminase or urease activities, demonstrating its potential as a promising antineoplastic agent.